Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity

International Journal of Cancer

Volumn 126, Issue 6, 2010, Pages 1428-1435

  Pilzer, David ^a   Saar, Moran ^a   Koya, Keizo ^b   Fishelson, Zvi ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Synta Pharmaceuticals Corp   (United States)

Author keywords

C9; Complement; Membrane attack complex; MKT 077; Mortalin

Indexed keywords

1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; COMPLEMENT; COMPLEMENT COMPONENT C9; COMPLEMENT MEMBRANE ATTACK COMPLEX; HEAT SHOCK PROTEIN 70; MORTALIN; SMALL INTERFERING RNA; STREPTOLYSIN O; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CELL DEATH; CELL SURFACE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ERYTHROCYTE; HEMOLYSIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; MEMBRANE VESICLE; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING;

ANIMALS; BACTERIAL PROTEINS; BLOTTING, WESTERN; CALCIMYCIN; CELL SURVIVAL; COMPLEMENT C9; DOSE-RESPONSE RELATIONSHIP, DRUG; HCT116 CELLS; HEMOLYSIS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IONOPHORES; K562 CELLS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; PYRIDINES; RABBITS; RECOMBINANT PROTEINS; RNA INTERFERENCE; STREPTOLYSINS; THIAZOLES;

EID: 74949095086     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24888     Document Type: Article

References (51)

1. Nollen EA, Morimoto RI. Chaperoning signaling pathways: molecular chaperones as stress-sensing 'heat shock' proteins. J Cell Sci 2002;115:2809-16.
2. Young JC, Agashe VR, Siegers K, Hartl FU. Pathways of chaperone-mediated protein folding in the cytosol. Nat Rev Mol Cell Biol 2004;5:781-91.
3. Ran Q, Wadhwa R, Kawai R, Kaul SC, Sifers RN, Bick RJ, Smith JR, Pereira-Smith OM. Extramitochondrial localization of mortalin/mthsp70/PBP74/ GRP75. Biochem Biophys Res Commun 2000;275:174-9.
4. Wadhwa R, Yaguchi T, Hasan MK, Mitsui Y, Reddel RR, Kaul SC. Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. Exp Cell Res 2002;274: 246-53.
5. Carette J, Lehnert S, Chow TY. Implication of PBP74/mortalin/GRP75 in the radioadaptive response. Int J Radiat Biol 2002;78:183-90.
6. Voisine C, Craig EA, Zufall N, von Ahsen O, Pfanner N, Voos W. The protein import motor of mitochondria: unfolding and trapping of preproteins are distinct and separable functions of matrix Hsp70. Cell 1999;97:565-74.
7. Ma Z, Izumi H, Kanai M, Kabuyama Y, Ahn NG, Fukasawa K. Mortalin controls centrosome duplication via modulating centrosomal localization of p53. Oncogene 2006;25:5377-90.
8. Mizukoshi E, Suzuki M, Loupatov A, Uruno T, Hayashi H, Misono T, Kaul SC, Wadhwa R, Imamura T. Fibroblast growth factor-1 interacts with the glucose-regulated protein GRP75/mortalin. Biochem J 1999;343 (Part 2):461-6.
9. Sacht G, Brigelius-Flohe R, Kiess M, Sztajer H, Flohe L. ATP-sensitive association of mortalin with the IL-1 receptor type I. Biofactors 1999;9:49-60.
10. Kaul SC, Duncan EL, Englezou A, Takano S, Reddel RR, Mitsui Y, Wadhwa R. Malignant transformation of NIH3T3 cells by overexpression of mot-2 protein. Oncogene 1998;17:907-11.
11. Kaul SC, Reddel RR, Sugihara T, Mitsui Y, Wadhwa R. Inactivation of p53 and life span extension of human diploid fibroblasts by mot-2. FEBS Lett 2000;474:159-64.
12. Dundas SR, Lawrie LC, Rooney PH, Murray GI. Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J Pathol 2005;205:74-81.
13. Pizzatti L, Sa LA, de Souza JM, Bisch PM, Abdelhay E. Altered protein profile in chronic myeloid leukemia chronic phase identified by a comparative proteomic study. Biochim Biophys Acta 2006;1764:929-42.
14. Takano S, Wadhwa R, Yoshii Y, Nose T, Kaul SC, Mitsui Y. Elevated levels of mortalin expression in human brain tumors. Exp Cell Res 1997;237:38-45.
15. Kaul SC, Yaguchi T, Taira K, Reddel RR, Wadhwa R. Overexpressed mortalin (mot-2)/mthsp70/GRP75 and hTERT cooperate to extend the in vitro lifespan of human fibroblasts. Exp Cell Res 2003;286:96-101.
16. Pilzer D, Fishelson Z. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis. Int Immunol 2005;17:1239-48.
17. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058-66.
18. Muller-Eberhard HJ. The membrane attack complex of complement. Annu Rev Immunol 1986;4:503-28.
19. Bohana-Kashtan O, Ziporen L, Donin N, Kraus S, Fishelson Z. Cell signals transduced by complement. Mol Immunol 2004;41:583-97.
20. Papadimitriou JC, Drachenberg CB, Shin ML, Trump BF. Ultrastructural studies of complement mediated cell death: a biological reaction model to plasma membrane injury. Virchows Arch 1994;424:677-85.
21. Fishelson Z, Attali G, Mevorach D. Complement and apoptosis. Mol Immunol 2001;38:207-19.
22. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003;40:109-23.
23. Carney DF, Koski CL, Shin ML. Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9. J Immunol 1985;134:1804-9.
24. Morgan BP, Dankert JR, Esser AF. Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J Immunol 1987;138:246-53.
25. Scolding NJ, Morgan BP, Houston WA, Linington C, Campbell AK, Compston DA. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature 1989;339:620-2.
26. Sims PJ, Wiedmer T. Repolarization of the membrane potential of blood platelets after complement damage: evidence for a Ca++-dependent exocytotic elimination of C5b-9 pores. Blood 1986;68:556-61.
27. Moskovich O, Fishelson Z. Live cell imaging of outward and inward vesiculation induced by the complement c5b-9 complex. J Biol Chem 2007;282:29977-86.
28. Wadhwa R, Takano S, Robert M, Yoshida A, Nomura H, Reddel RR, Mitsui Y, Kaul SC. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J Biol Chem 1998;273:29586-91.
29. Koya K, Li Y, Wang H, Ukai T, Tatsuta N, Kawakami M, Shishido,Chen LB. MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. Cancer Res 1996;56:538-43.
30. Wadhwa R, Sugihara T, Yoshida A, Nomura H, Reddel RR, Simpson R, Maruta H, Kaul SC. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res 2000;60:6818-21.
31. Chiba Y, Kubota T, Watanabe M, Otani Y, Teramoto T, Matsumoto Y, Koya K, Kitajima M. Selective antitumor activity of MKT-077, a delocalized lipophilic cation, on normal cells and cancer cells in vitro. J Surg Oncol 1998;69:105-10.
32. Modica-Napolitano JS, Koya K, Weisberg E, Brunelli BT, Li Y, Chen LB. Selective damage to carcinoma mitochondria by the rhodacyanine MKT-077. Cancer Res 1996;56:544-50.
33. Petit T, Izbicka E, Lawrence RA, Nalin C, Weitman SD, Von Hoff DD. Activity of MKT 077, a rhodacyanine dye, against human tumor colony-forming units. Anticancer Drugs 1999;10:309-15.
34. Tatsuta N, Suzuki N, Mochizuki T, Koya K, Kawakami M, Shishido T, Motoji N, Kuroiwa H, Shigematsu A, Chen LB. Pharmacokinetic analysis and antitumor efficacy of MKT-077, a novel antitumor agent. Cancer Chemother Pharmacol 1999;43:295-301.
35. Reiter Y, Fishelson Z. Complement membrane attack complexes induce in human leukemic cells rapid expression of large proteins (L-CIP). Mol Immunol 1992;29:771-81.
36. Fishelson Z, Horstmann RD, Muller-Eberhard HJ. Regulation of the alternative pathway of complement by pH. J Immunol 1987;138:3392-5.
37. Tschopp J. Circular polymerization of the membranolytic ninth component of complement. Dependence on metal ions. J Biol Chem 1984;259:10569-73.
38. Bhakdi S, Tranum-Jensen J, Sziegoleit A. Mechanism of membrane damage by streptolysin-O. Infect Immun 1985;47:52-60.
39. Reiter Y, Ciobotariu A, Jones J, Morgan BP, Fishelson Z. Complement membrane attack complex, perforin, and bacterial exotoxins induce in K562 cells calcium-dependent cross-protection from lysis. J Immunol 1995;155:2203-10.
40. Siraganian RP, Kulczycki A, Jr, Mendoza G, Metzger H. Ionophore A-23187 induced histamine release from rat mast cells and rat basophil leukemia (RBL-1) cells. J Immunol 1975;115:1599-602.
41. Kraus S, Fishelson Z. Cell desensitization by sublytic C5b-9 complexes and calcium ionophores depends on activation of protein kinase C. Eur J Immunol 2000;30:1272-80.
42. Pilzer D, Gasser O, Moskovich O, Schifferli JA, Fishelson Z. Emission of membrane vesicles: roles in complement resistance, immunity and cancer. Springer Semin Immunopathol 2005;27:375-87.
43. Morgan BP, Luzio JP, Campbell AK. Intracellular Ca2+ and cell injury: a paradoxical role of Ca2+ in complement membrane attack. Cell Calcium 1986;7:399-411.
44. Morgan BP, Luzio JP, Campbell AK. Inhibition of complement-induced [14C]sucrose release by intracellular and extracellular monoclonal antibodies to C9: evidence that C9 is a transmembrane protein. Biochem Biophys Res Commun 1984;118:616-22.
45. Britten CD, Rowinsky EK, Baker SD, Weiss GR, Smith L, Stephenson J, Rothenberg M, Smetzer L, Cramer J, Collins W, Von Hoff DD, Eckhardt SG. A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077. Clin Cancer Res 2000;6:42-9.
46. Propper DJ, Braybrooke JP, Taylor DJ, Lodi R, Styles P, Cramer JA, Collins WC, Levitt NC, Talbot DC, Ganesan TS, Harris AL. Phase I trial of the selective mitochondrial toxin MKT077 in chemoresistant solid tumours. Ann Oncol 1999;10:923-7.
47. Loberg RD, Day LL, Dunn R, Kalikin LM, Pienta KJ. Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 2006;8:69-78.
48. Terui Y, Sakurai T, Mishima Y, Sugimura N, Sasaoka C, Kojima K, Yokoyama M, Mizunuma N, Takahashi S, Ito Y, Hatake K. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Sci 2006;97:72-9.
49. Zell S, Geis N, Rutz R, Schultz S, Giese T, Kirschfink M. Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (SODNs) sensitizes tumour cells to complement attack. Clin Exp Immunol 2007;150:576-84.
50. Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R, Amadori A, Tedesco F. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007;67:10556-63.
51. Wadhwa R, Takano S, Taira K, Kaul SC. Reduction in mortalin level by its antisense expression causes senescence-like growth arrest in human immortalized cells. J Gene Med 2004;6:439-44.